Background: Embolic infarctions from the heart are known to cause multiple scattered infarct lesions as well as single, large territorial infarctions. However, it remains unknown which factors contribute to these different infarction patterns in patients with potential cardiac sources of embolism (PCSE). Methods: We examined 388 ischemic stroke patients with a high-risk PCSE using diffusion-weighted imaging. Infarction patterns were categorized into a single large lesion, a single small lesion, confluent and additional lesions, or small scattered lesions. The relationships between infarction patterns and clinical and hematologic parameters were investigated. Results: Of the 388 patients, a single large lesion was detected in 139 (35.8%), a single small lesion in 29 (7.5%), confluent and additional lesions in 171 (44.1%), and small scattered lesions in 49 (12.7%). Prior use of antiplatelet agents and anticoagulant were associated with the pattern of small scattered lesions and a single small lesion, respectively. Additionally, higher white blood cell counts were associated with confluent and additional lesions. The type of high-risk PCSE was not related to a specific infarction pattern. Conclusions: These results suggest that platelet function and inflammatory processes may directly affect the thrombus formation in the cardiac chamber.

Keywords:
Ischemic stroke, Embolism, Diffusion-weighted image
1.
Baird AE, Lovblad KO, Schlaug G, Edelman RR, Warach S: Multiple acute stroke syndrome: marker of embolic disease? Neurology 2000;54:674–678.
2.
Doufekias E, Segal AZ, Kizer JR: Cardiogenic and aortogenic brain embolism. J Am Coll Cardiol 2008;51:1049–1059.
3.
Koennecke HC, Bernarding J, Braun J, Faulstich A, Hofmeister C, Nohr R, Leistner S, Marx P: Scattered brain infarct pattern on diffusion-weighted magnetic resonance imaging in patients with acute ischemic stroke. Cerebrovasc Dis 2001;11:157–163.
4.
Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, Price TR, Hier DB: Brain infarction severity differs according to cardiac or arterial embolic source. Neurology 1993;43:728–733.
5.
Kang DW, Chalela JA, Ezzeddine MA, Warach S: Association of ischemic lesion patterns on early diffusion-weighted imaging with toast stroke subtypes. Arch Neurol 2003;60:1730–1734.
6.
Wessels T, Wessels C, Ellsiepen A, Reuter I, Trittmacher S, Stolz E, Jauss M: Contribution of diffusion-weighted imaging in determination of stroke etiology. AJNR Am J Neuroradiol 2006;27:35–39.
7.
Watson T, Shantsila E, Lip GY: Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155–166.
8.
Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR: Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995;37:231–241.
9.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial: TOAST – Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
10.
Lee BI, Nam HS, Heo JH, Kim DI: Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 2001;12:145–151.
11.
Han SW, Nam HS, Kim SH, Lee JY, Lee KY, Heo JH: Frequency and significance of cardiac sources of embolism in the toast classification. Cerebrovasc Dis 2007;24:463–468.
12.
Bendszus M, Koltzenburg M, Burger R, Warmuth-Metz M, Hofmann E, Solymosi L: Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study. Lancet 1999;354:1594–1597.
13.
Ogata J, Yutani C, Otsubo R, Yamanishi H, Naritomi H, Yamaguchi T, Minematsu K: Heart and vessel pathology underlying brain infarction in 142 stroke patients. Ann Neurol 2008;63:770–781.
14.
Jauss M, Wessels T, Trittmacher S, Allendorfer J, Kaps M: Embolic lesion pattern in stroke patients with patent foramen ovale compared with patients lacking an embolic source. Stroke 2006;37:2159–2161.
15.
Singhal AB, Topcuoglu MA, Buonanno FS: Acute ischemic stroke patterns in infective and nonbacterial thrombotic endocarditis: a diffusion-weighted magnetic resonance imaging study. Stroke 2002;33:1267–1273.
16.
Wolberg AS: Thrombin generation and fibrin clot structure. Blood Rev 2007;21:131–142.
17.
Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY: Platelet P-selectin levels in relation to plasma soluble P-selectin and β-thromboglobulin levels in atrial fibrillation. Stroke 2002;33:1237–1242.
18.
Issac TT, Dokainish H, Lakkis NM: Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50:2021–2028.
19.
Conway DS, Buggins P, Hughes E, Lip GY: Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004;43:2075–2082.
20.
Conway DS, Buggins P, Hughes E, Lip GY: Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004;93:1368–1373, A1366.
21.
Audebert HJ, Rott MM, Eck T, Haberl RL: Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke 2004;35:2128–2133.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.